英国癌症基因组学的公平性:一项全国癌症队列的横断面分析
该横断面分析评估了英国国家医疗服务体系(NHS)英格兰的癌症变异优先排序流程在族裔和祖先多样化人群中的表现,并分析了10万基因组计划癌症队列对英格兰人群的代表性。研究发现,与非欧洲祖先患者相比,欧洲祖先患者中可操作基因的肿瘤突变检出更多,而非欧洲祖先患者中潜在致病性胚系变异过多,可能阻碍诊断过程。
要点
- 10万基因组计划癌症队列中多样化族裔群体的代表性不低于国家统计数据。
- 黑人女性乳腺癌招募率比(2.2)高于全国数据(0.81),黑人男性前列腺癌和膀胱癌及亚洲女性乳腺癌的招募率比也高于全国数据。
- 非欧洲祖先患者中潜在致病性变异过多,但可操作基因的肿瘤突变检出较少。
核心结论
- 非欧洲祖先患者中潜在致病性胚系变异过多,可能阻碍诊断过程;需要改进变异优先排序流程并在多样化群体中开展更多研究,以确保癌症护理中基因组学的公平实施。
研究设计与样本
- 横断面分析,分析2015年2月至2018年12月期间招募入10万基因组计划的癌症患者的全基因组测序数据,临床信息来自NHS英格兰国家癌症登记和分析服务。
- 排除癌症类型少于5例的患者、血液系统癌症、儿童癌症、原发灶不明癌、性别不确定的患者以及基因中缺失体细胞突变的患者。
- 通过计算自我报告的族裔的招募率比来评估10万基因组计划中族裔代表性,并分析潜在致病性变异的分类率差异以评估不同祖先群体的胚系和体细胞突变差异。
主要发现
- 2015年2月至2018年12月期间,10万基因组计划共招募14 775例癌症患者。
- 与国家统计数据相比,10万基因组计划中多样化族裔群体没有代表性不足的证据。
- 乳腺癌招募率比:黑人女性 vs 白人女性在10万基因组计划中为2.2(95%CI 1.6-3.0),全国数据中为0.81(95%CI 0.79-0.83),率比倍数变化为2.7(95%CI 2.0-3.7,p<0.0001)。
- 前列腺癌黑人男性 vs 白人男性率比倍数变化为3.7(95%CI 1.8-7.5,p=0.0004);膀胱癌黑人男性 vs 白人男性率比倍数变化为6.1(95%CI 2.0-18.8,p=0.0016);乳腺癌亚洲女性 vs 白人女性率比倍数变化为1.4(95%CI 1.2-1.7,p=0.0008)。
- 祖先与携带潜在致病性变异的可能性显著相关(似然比检验 p=0.0011);南亚裔500例中23例(4.6%)检出潜在致病性变异(调整模型OR 1.88,95%CI 1.21-2.93,p=0.0052),非洲裔453例中24例(5.3%)检出(OR 2.24,95%CI 1.44-3.48,p=0.0003),欧洲祖先11 955例中263例(2.2%)检出。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most research on genetic screening and precision oncology is based on individuals of European ancestry. We applied the National Health Service (NHS) England's cancer variant prioritisation workflow to evaluate the performance of these approaches in ethinically and ancestrally diverse populations. The second aim of the study was to assess the representativeness of the 100 000 Genomes Project cancer cohort of the population of England. METHODS: In this cross-sectional analysis, whole-genome sequencing data from patients with cancer recruited into the 100 000 Genomes Project between February 2015 to December 2018 were analysed. Clinical information, including tumour stage and grade, was gathered from the NHS England National Cancer Registration and Analysis Service. Patients with cancer types with fewer than five individuals, haematological cancers, childhood cancers, unknown primary carcinomas, patients with indeterminate sex, and patients missing somatic mutations in genes were excluded. To assess ethnicity representation in the 100 000 Genomes Project, we calculated the recruitment ratios for self-reported ethnicities for patients with cancer recruited to the 100 000 Genomes Project and patients with cancer in England. We also analysed differences in classification rates for potentially pathogenic variants to assess ancestry-related differences in germline and somatic mutations of different ancestry groups. FINDINGS: 14 775 patients with cancer were recruited between February, 2015, and December, 2018, into the 100 000 Genomes Project. There was no evidence of under-representation of diverse ethnic groups in the 100 000 Genomes Project when compared with the national statistics. The recruitment rate ratio for breast cancer was 2·2 (95% CI 1·6-3·0) for Black versus White women in the 100 000 Genomes Project compared with 0·81 (0·79-0·83) for Black versus White women in the national data (fold-change in rate ratios 2·7; 95% CI 2·0-3·7, p<0·0001), suggesting higher representation of Black women in the 100 000 Genomes Project than expected given the ethnicity-specific incidence rates in England. Compared with national rates, the 100 000 Genomes Project also had higher recruitment rates of Black versus White men with prostate cancer (fold-change in rate ratios 3·7; 1·8-7·5, p=0·0004), Black versus White men with bladder cancer (fold change in rate ratios 6·1; 2·0-18·8, p=0·0016), and Asian versus White women with breast cancer (fold change in rate ratios 1·4; 1·2-1·7, p=0·0008). Ancestry had a significant association with the likelihood of carrying a variant classified as a potentially pathogenic (likelihood ratio test p=0·0011). Potentially pathogenic variants were identified in 23 (4·6%) of 500 South Asian (adjusted model odds ratio [OR] 1·88, 95% CI 1·21-2·93, p=0·0052) and 24 (5·3%) of 453 African ancestry patients (OR 2·24, 1·44-3·48, p=0·0003) compared with 263 (2·2%) of 11 955 in European-ancestry patients. However, we found that fewer tumour mutations in actionable genes were identified for patients of non-European ancestry compared with patients of European ancestry when adjusting for sex and cancer type (likelihood ratio test p<0·0001). INTERPRETATION: The was an excess of germline variants classified as potentially pathogenic variants in patients with non-European ancestry, which might impede the diagnostic process. Improved variant prioritisation workflows and more research in diverse groups are needed to ensure equitable implementation of genomics in cancer care. FUNDING: The UK Department of Health and Social Care and the EU's Horizon 2020 Research and Innovation Programme.
引用
- Nguyen T, Tallman S, Cho Y, et al. Equity in cancer genomics in the UK: a cross-sectional analysis of a national cancer cohort. Lancet Oncol. 2025. PMID: 40513587. doi:10.1016/S1470-2045(25)00199-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。